For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Amrize Ltd. (AMRZ) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -17 (−100…+100 Quality+Value blend) · Quality 45 · Value -68 · Sentiment -11 (timing only, not weighted) · Composite fair value $43.15 vs $50.72 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Amrize Ltd.
AMRZ NYSEAmrize Ltd. is a building solutions company specializing in materials and systems for the North American construction market. Based in Chicago, Illinois and founded in 2023, the company serves residential, commercial, and infrastructure projects through two primary segments: building materials and building envelope. The building materials segment provides core construction inputs such as cement, aggregates, ready-mix concrete, and asphalt, which are used in roads, foundations, and structural elements. The building envelope segment focuses on the outer protective layer of buildings, offering advanced roofing and wall systems, including single-ply membranes, insulation, shingles, sheathing, waterproofing products, and protective coatings, as well as related adhesives, tapes, and sealants. Amrize Ltd. plays a key role in the broader basic materials and construction ecosystem by supplying integrated solutions that support durability, weather resistance, and energy performance across diverse building types and infrastructure projects in North America.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.14
Total Equity: $13.25B
Shares: 553,600,000
Total Debt: $0.00
Cash: $1.92B
EBITDA: $2.66B
Total Debt: $0.00
Cash: $1.92B
Revenue: $11.82B
Revenue: $11.82B
Revenue: $11.82B
Total Equity: $13.25B
Tax Rate: 21.8%
Equity: $13.25B
Total Debt: $0.00
Cash: $1.92B
Current Liabilities: $2.86B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $13.25B
Shares: 553,600,000
Shares: 553,600,000
CapEx: -$788.00M
Shares: 553,600,000
Stock Price: $50.36
Net Income: $1.19B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 3, 2026 12:03pm (20d ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $11.7B | $11.7B | $11.8B |
| Cost of Revenue | $8.9B | $8.6B | $8.8B |
| Gross Profit | $2.8B | $3.1B | $3.0B |
| Operating Expenses | $881.0M | $875.0M | $1.1B |
| Operating Income | $1.9B | $2.2B | $1.9B |
| Net Income | $956.0M | $1.3B | $1.2B |
| EBITDA | $2.6B | $2.9B | $2.7B |
| EPS | $1.73 | $2.30 | $2.14 |
| EPS (Diluted) | $1.73 | $2.30 | $2.14 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 11:33am (20d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | — | — | $1.6B | $1.9B |
| Total Current Assets | — | — | $4.8B | $4.7B |
| Total Assets | — | — | $23.8B | $24.2B |
| Current Liabilities | — | — | $2.6B | $2.9B |
| Long-Term Debt | — | — | — | — |
| Total Liabilities | — | — | $13.9B | $11.0B |
| Total Equity | $8.2B | $9.2B | $9.9B | $13.3B |
| Retained Earnings | — | — | $0 | $902.0M |
Cash Flow (Annual)
Last updated: Aug 3, 2026 12:03pm (20d ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | $2.0B | $2.3B | $2.2B |
| Capital Expenditure | -$630.0M | -$642.0M | -$788.0M |
| Free Cash Flow | $1.4B | $1.6B | $1.4B |
| Acquisitions (net) | -$1.6B | -$249.0M | -$86.0M |
| Net Debt Issued / (Repaid) | $0 | $0 | $3.4B |
| Dividends Paid | — | — | — |
| Stock Buybacks | — | — | — |
| Net Change in Cash | $756.0M | $478.0M | $337.0M |
Growth Trends (YoY %)
Last updated: Aug 3, 2026 12:03pm (20d ago)| Metric | 2024 | 2025 |
|---|---|---|
| Revenue Growth | +0.2% | +0.9% |
| Gross Profit Growth | +10.9% | -1.2% |
| Operating Income Growth | +16.3% | -13.2% |
| Net Income Growth | +33.3% | -7.0% |
| EBITDA Growth | +13.7% | -9.1% |
Dividend History (Last 20)
Last updated: Aug 3, 2026 11:34am (20d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-12 | $0.11 | — | — | — |
| 2026-04-24 | $0.44 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:29Even the bull case prices 36% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 70%.
| Case | Growth | Margin | Fair value | vs price ($50.72) |
|---|---|---|---|---|
| Bull — recovery | +7% | 16.3% | $32.34 | -36% |
| Base — stabilizes | +4% | 14.2% | $26.57 | -48% |
| Bear — keeps slipping | +2% | 12.1% | $21.43 | -58% |
| Stress — last quarter repeats | -1% | 8.9% | $15.04 | -70% |
Narrative Economics
market-narrative step).
Claude Reading
The raw quarterly cadence tells a clearer story than the models let on. Q1 is structurally a loss quarter for this business — Q1'25 was -$87M and Q1'26 is -$116M, so seasonality is real, but the YoY deterioration is not seasonality: Q1'26 revenue of $2.18B vs Q1'25's $2.08B is only +4.8% top line while the loss deepened by 33%. More concerning is Q4'25 at $2.84B revenue and $298M NI (10.5% margin) versus what Q4 normally should look like for a business that did $3.68B/14.8% in Q3'25 — that's a sharp sequential deceleration into year-end. Full-year 2025 revenue of $11.82B vs 2024's $11.70B is essentially flat (+1%), and 2025 NI of $1.19B is actually *down* from 2024's $1.27B. The "earnings CAGR of 11.3%" is a three-year artifact anchored on a weak 2023 base ($956M); the recent trajectory is negative, not compounding.
On the models: the classification as "mature_earner" is right but the pre-flight framing that this is a 23.5x P/E premium to VMC/MLM is somewhat misleading — AMRZ trades at 9.4x EV/EBITDA, which is a *discount* to Vulcan and Martin Marietta (both routinely 15-18x EV/EBITDA). The P/E premium reflects a lower-margin business mix (net margin 10% vs VMC/MLM at 15%+), not investor enthusiasm. So the synthesis verdict of "market prices in more growth than projected" is arguably backwards on the EV/EBITDA lens — this is priced closer to a Summit Materials or Eagle Materials than to the aggregates royalty comps. The DCF-implied $42 fair value assumes flat-ish cash generation, which given TTM FCF of ~$1.42B on a $27B market cap (5.2% FCF yield) and zero reported debt is not obviously punitive. I think the synthesis is too bearish on multiple grounds: it's ignoring the balance sheet optionality (net cash, $13.25B equity, 0 debt-to-equity) and the fact that Amrize can lever up meaningfully to fund the consolidation thesis without stress.
The contrarian case worth taking seriously: this is a June 2023 spin from Holcim, and the "flat revenue" 2023→2025 exactly coincides with the North American residential construction downturn and elevated rates. If housing starts inflect and non-residential retrofit spending accelerates (IRA-driven envelope demand is real), operating leverage in a business with 25.7% gross margin and $788M annual capex is meaningful — a 200bps op margin expansion on $12B is $240M of incremental EBIT, roughly 20% earnings accretion. The insider buying pattern in May 2026 is genuinely striking: eight separate purchases in a single week ($19-22) totaling ~20,000 shares at ~$50 is not routine 10b5-1 behavior — that's cluster buying after what was presumably a weak Q1 print, which is the textbook signal of insiders believing the cycle low is in. The models flag this but don't weight it enough.
Where I'd push back on my own contrarianism: the "significant insider buying" is small in dollar terms (~$1M total across all purchases at $50), the debt line showing "—" is a data-quality flag not a confirmed zero (a $13B equity building materials company with truly zero debt would be nearly unique), and the declining quarterly revenue trend is real. Macro headwinds flagged by the sector signal are consistent with what commercial construction indices show. The narrative layer's characterization as a "moderate intensity, anchored" steady-compounder story is fair — this isn't a cult stock, it's an execution story that either works or doesn't over 2-3 years. I'll dissent from the synthesis's "fair-to-modestly-overvalued at $42" read: on EV/EBITDA (9.4x) with net cash, an underlevered balance sheet, insider cluster buying at current prices, and a plausible cyclical trough in Q1 numbers, this looks closer to fair-to-cheap than to 16% overvalued. Fair value in the $52-58 range is defensible if you believe 2024 margins (16% net margin quarters) are the through-cycle norm rather than the peak. The risk is that they *were* the peak and 2025's deterioration is structural mix shift from the building envelope integration — which is unknowable without segment detail we don't have here.
GPT Reading
What jumps out is how little top-line growth investors are getting for a $27.1B equity value. Revenue was $11.82B in 2025 versus $11.70B in 2024 and $11.68B in 2023: essentially flat for three years. Yet the stock trades at 2.36x sales, 23.5x earnings, and about 19x free cash flow on 2025’s $1.42B FCF. That would be easier to defend if margins were expanding cleanly, but they are not. Gross profit actually slipped from $3.07B in 2024 to $3.03B in 2025, operating income fell from $2.20B to $1.91B, and net income dropped from $1.27B to $1.19B despite stable revenue. So the multiple is being paid on a business that is currently proving resilient, not growing, and whose profitability has already moved off peak.
The quarterly pattern reinforces that this is a cyclical building materials company with pronounced seasonality, not a steady compounder. Q1 is loss-making in both observed years: -$87M on $2.08B revenue in 2025 and -$116M on $2.18B in 2026. The “good” quarters are the construction season quarters, but even there the exit rate softened: Q3 2025 net margin was 14.8% versus 16.0% in Q3 2024, and Q4 2025 margin was 10.5%. Full-year 2025 operating margin of 16.1% remains good, but it is down from 18.8% in 2024. If I annualize the latest twelve months from the quarterly data provided, net income is about $1.16B, basically in line with 2025, which means the business is treading water while the market affords it a premium multiple. For a producer tied to construction activity and input costs, paying more than 9.4x EV/EBITDA for flat sales and declining EBIT looks rich.
The best part of the story is the balance sheet and cash conversion. Cash of $1.92B, debt-to-equity shown at zero, current ratio 1.64, and operating cash flow of $2.21B give Amrize real durability and optionality. FCF of $1.42B is substantial, and ROIC at 13.2% says this is not a bad business. The insider tape is also notable: multiple open-market purchases in May 2026, including 7,000 shares and several 1,000-3,000 share buys, suggest management or directors saw value after some weakness. But those positives argue for downside support, not for a premium valuation. A fortress balance sheet can justify not trading at a distressed multiple; it does not, by itself, justify a growth-stock multiple on a cyclical materials name whose revenue CAGR is barely above zero.
The strongest argument against my skepticism is that the market may be looking through a margin dip and valuing latent operating leverage plus capital deployment. If the company truly has no meaningful debt, then nearly the entire enterprise value is equity, and 9.4x EV/EBITDA is not egregious for a high-quality North American materials platform with double-digit ROIC, decent gross margins around 25.7%, and room to do accretive M&A or buybacks. The quarterly revenue line is also not collapsing: Q1 2026 revenue grew to $2.18B from $2.08B, and 2025’s stronger middle quarters of $3.22B and $3.68B suggest end-market demand held up. A bull would say 2024 represented unsustainably high margins, 2025 is the reset year, and paying 23x trough-ish earnings for a debt-free compounder-in-formation is reasonable. I weigh that differently because there is no evidence yet of renewed growth or of a post-reset earnings ramp; until that shows up, the premium is narrative-led.
What would change my mind is simple: I need to see either growth or a materially better valuation. If the next peak-season quarters can push revenue meaningfully above prior highs — for example, Q3 above $3.8B — while restoring net margin toward 15%-16% and lifting annualized net income back toward $1.3B-$1.4B, then today’s price starts to make more sense. Alternatively, if the stock falls into the low $40s without a deterioration in FCF, the risk/reward gets more compelling because you would be paying closer to 15x-17x earnings and roughly 7.5x-8.5x EV/EBITDA for a debt-light franchise. At $50.36, I think investors are paying in advance for an improvement the numbers have not yet delivered.
Grok Reading
The raw numbers describe a no-growth cyclical that is being asked to carry a growth multiple. Revenue crawled from $11.68B in 2023 to $11.70B in 2024 to $11.82B in 2025—a 0.6% CAGR that matches the computed momentum print exactly—while operating income fell from $2.20B to $1.91B and net income slipped from $1.27B to $1.19B. Gross margin compressed from the prior year and the most recent peak quarter (Q3 2025) delivered $3.68B at a 14.8% net margin versus $3.45B at 16% a year earlier; volume or mix improved, pricing or cost did not. Q1 is seasonally loss-making in this industry, yet the loss widened from –$87M to –$116M even as revenue ticked up 5% to $2.18B, a sign that fixed-cost absorption is not improving. Free cash flow of $1.42B on a $27B equity value produces a 5.2% FCF yield; at 23.5× trailing earnings and 9.4× EV/EBITDA that is simply too thin a yield for a business whose top line is stagnant and whose operating leverage is pointing the wrong way. Peer aggregates names historically clear 18–21×; Amrize sits at a clear premium with inferior growth and ROE of only 8.9%.
The balance sheet is the one unambiguous bright spot—zero reported debt, $1.92B cash, current ratio 1.64, and ROIC still a respectable 13.2%—and it underwrites the optionality that the market narrative leans on. But optionality is not earnings. The 2025 operating-margin drop from roughly 18.8% to 16.1% already shows that scale advantages in procurement have not yet translated into durable expansion; until they do, the 20% premium to the ~$42 composite fair-value estimate is pure story. Insider open-market buying in May 2026 (clustered purchases totaling well over 20k shares) is real and deserves weight, yet it cannot rewrite a revenue CAGR of 0.6% or reverse the year-over-year earnings decline of 7%.
The strongest counter-argument is straightforward: a fortress balance sheet plus aggressive insider accumulation in a misunderstood 2023 spin-off can re-rate a name before the income statement catches up, especially if the building-envelope mix shift and any tuck-in M&A begin to lift margins in the second half of 2026. EV/EBITDA of 9.4× is not egregious for a clean-capital-structure materials name, FCF conversion remains solid, and a construction up-cycle or energy-efficiency retrofit wave could suddenly make the flat revenue base look like a trough. I weigh that less heavily because the same data already contain the early test of that thesis—2025 was supposed to be the year operational improvements appeared—and instead operating profit declined $290M while revenue was essentially unchanged. Narrative durability is explicitly tagged moderate; once the construction cycle or an earnings miss challenges the “quality compounder” label, the multiple has a clear path back to mid-teens.
I would flip to neutral or constructive only on two concrete prints: trailing-twelve-month revenue growth sustained above 4–5% with operating margin reclaiming the 18% zone, or a announced capital-deployment action (accretive M&A or accelerated buyback) large enough to move the earnings power by at least 10% within twelve months. Absent those, the stock is priced for a story the financials have so far refused to tell.
Big-3 Panel — where each AI stands
Claude — Second Response · fairly valued changed direction
VERDICT: Fairly valued at $50 — fair range $46-52 on 9.4x EV/EBITDA with net cash; wait for either margin recovery to 18% or a pullback to low-$40s before adding.
Both colleagues hit the same anvil: revenue has been flat for three years, operating income fell $290M in 2025 on essentially unchanged sales, and Q1'26 losses deepened despite modest revenue growth. That combination — flat top line plus negative operating leverage — is genuinely harder to defend than my first read gave credit for. GPT's point that "2025 was supposed to be the reset/improvement year and instead margins compressed" is the argument that lands hardest against my cyclical-trough framing. If Q3'25 net margin already slipped from 16.0% to 14.8% at *peak season revenue* of $3.68B, that's not a demand problem being masked — that's mix or cost, and it undermines my "200bps margin expansion available" bull case. I underweighted this in the first pass by anchoring on the 2024 margin profile as normal rather than as peak.
Where I still push back: neither colleague seriously engages the EV/EBITDA-vs-peers point. VMC and MLM trade 15-18x EV/EBITDA; AMRZ at 9.4x with net cash is not a premium multiple on the enterprise-value lens, it's a discount, and the P/E premium is a function of lower net margin mix (cement/envelope vs pure aggregates), not investor exuberance. Grok's "peers clear 18-21x P/E" comparison mixes aggregate royalty models with integrated materials — not the right comp set. And the insider cluster in May 2026 remains meaningful as a signal even if small in dollars: eight separate purchases in one week at $19-22 range is behavioral evidence that the people with segment-level visibility saw the Q1 print as noise, not signal.
Net: I'm revising down from "modestly undervalued" to "fairly valued," but not to overvalued. The colleagues convinced me that operating leverage is pointing the wrong way and 2025 is not obviously a trough; they did not convince me the EV/EBITDA multiple is rich or that the balance sheet optionality is properly discounted. Fair value $46-52, current $50 is inside that band.
GPT — Second Response · fairly valued changed direction
VERDICT: Fair-to-slightly overvalued at $50.36; reasonable value looks closer to $46-$50 today, with upside to $52-$55 only if margins recover toward 2024 levels.
Claude’s pushback on my P/E framing is the only argument that materially moved me: for a capital-structure-light materials business, EV/EBITDA is the cleaner anchor, and 9.4x is not obviously expensive against quality building-material peers. I also underweighted the significance of a spin/reset context: if 2024 was not “normal” but instead one point in a post-spin integration and housing slowdown, then valuing 2025 as the settled earnings base is too static. That said, his bull case still depends on a margin recovery that is not in evidence. The same quarterly facts he cites cut both ways: Q1’26 revenue rose 4.8% yet the loss deepened, and Q4’25 showed real deceleration. The insider cluster buying is supportive, but I agree with his own caveat that roughly $1M of purchases is a signal, not a valuation floor.
Grok largely reinforced my original caution. The key issue remains unchanged: this is a resilient business, but not yet a demonstrable grower. Flat 2023–2025 revenue, lower 2025 gross profit, and a 270 bps operating-margin decline from 2024 to 2025 make it hard to pay today for tomorrow’s operating leverage. Where I do revise is in degree, not direction: calling it plainly “overvalued” at $50 may have been a bit too severe given the likely stronger EV-based relative case, cash-rich balance sheet, and realistic strategic optionality. I now think the right posture is closer to fair-to-slightly-overvalued unless and until peak-season quarters prove margins can move back toward 2024 levels. In price terms, I’d no longer insist on low-$40s as the only attractive zone; mid-$40s would already make the setup more balanced, while sustained evidence of >$1.3B annual earnings power would justify low-to-mid $50s.
Grok — Second Response · overvalued held
VERDICT: Overvalued at $50.36 vs $40-44 intrinsic; flat sales + falling EBIT still do not support 23.5× PE / 9.4× EV/EBITDA
Claude’s EV/EBITDA framing and trough-cycle optimism are the only points that required a hard second look. Yes, 9.4× EV/EBITDA sits below VMC/MLM’s 15-18× range, and the net-cash/under-levered sheet plus May 2026 cluster buying do create real optionality. But Claude himself flags the buying as only ~$1 M total and the “zero debt” line as a possible data artifact; more importantly, the same quarterly tape he cites shows the deterioration is not pure seasonality—Q1 loss widened 33 % on modest revenue growth, Q4 margins compressed sharply, and full-year EBIT fell $290 M on flat sales. That is not the clean reset a 200 bps margin rebound story needs. GPT’s parallel reading correctly keeps the focus on the 0.6 % revenue CAGR and the 23.5× PE / 19× FCF multiples being paid for a business still proving resilience rather than growth.
Nothing in either colleague’s note supplies the missing evidence of sustained top-line acceleration or margin reclamation that I originally required. The fortress balance sheet justifies a floor, not a premium; until TTM revenue growth clears 4-5 % with operating margins back near 18 %, or capital deployment visibly lifts earnings power 10 %, the multiple remains narrative-led. I therefore hold the original valuation anchor.
Advanced Analysis Forensic deep-dive · separate lenses
Amrize prints roughly $11.7-11.8B in revenue with gross margins in the 24-26% range and operating margins of 16-19%, producing $1.19B net income and $1.42B FCF in 2025. OCF/NI of 1.93x and accruals at -4.2% of assets indicate the earnings are cash-backed and not flattered by working-capital gimmicks. The balance sheet carries $1.92B net cash and the business self-funds capex without recourse to external capital.
Share count is essentially frozen (553.1M to 553.6M over three years, 0.1% CAGR) with SBC at a negligible 0.1% of revenue, so per-share economics are protected. Management behavior reinforces the read: 16 open-market P-purchases totaling $2.7M in the past year, led by CEO Jenisch stacking multiple lots on 5/15 and 5/19, with CFO/other officers also buying, and zero insider sells. That is a clean, concentrated conviction pattern, not scattered token buys.
The blemishes are real but modest: revenue is flat (11.68 to 11.82B, sub-1% growth), operating margin gave back 270bps from 2024 to 2025 (18.8 to 16.1), net income fell from $1.27B to $1.19B, and Altman Z at 2.37 sits in the grey zone, suggesting the capital structure carries more leverage than the net-cash figure alone implies (likely gross debt is meaningful). Cyclical building-materials exposure limits durability confidence.
Verify before trusting this (6)
- Gross debt level and maturity schedule behind the 2.37 Altman Z despite $1.92B net cash
- Whether the 2025 operating margin compression is volume, price/cost, or mix-driven
- Segment and geographic revenue mix and any customer concentration
- Capex intensity vs. maintenance capex to gauge sustainability of the $1.42B FCF
- Details of the spin from Holcim and any residual related-party arrangements
- Capital allocation policy — buyback authorization, dividend intent, M&A appetite
The composite fair value lands at $41.21 and the signal-adjusted value at $42.24, implying about -16% to -19% downside from $50.72. The two more conservative methods corroborate: DCF at $34.82 and EPV floor at $30.90 both sit well below the tape. Only the anchored-PE method ($64.31) supports the current price, and that method leans on peer multiples that may already reflect cycle-peak earnings in building materials - I would not let it override two cash-based methods pointing lower.
Verify before trusting this (5)
- Segment-level organic growth ex-acquisitions to test whether the flat top line is mix or genuine stagnation
- 2025 margin bridge - is the give-back one-off (integration, input costs) or structural
- Net debt including lease and pension liabilities to validate the grey-zone Altman Z read
- Forward guidance on capex intensity and M&A pipeline pricing
- Peer multiple comparability - are anchored PE peers at similar cycle position
AMRZ sits inside a neutral-to-slightly-constructive tape (VIX 16, S&P just 1.6% off highs) but faces the standard macro drag of a 4.68% 10y and a market PE near 27. For a freshly spun-out building-materials roll-up, that mix is a mild crosswind: rates weigh on cyclical construction names, but there's no risk-off panic to force sellers. The narrative is a steady-compounder consolidation play with moderate intensity, moderate durability, and low cult - a story that supports the 20% premium to DCF but doesn't generate the kind of enthusiasm that carries a stock through a rough patch. Momentum is quietly positive with low revenue volatility, which fits the compounder framing. News flow is essentially empty for AMRZ itself; the only tangential item is a peer (ROAD) earnings preview flagging a likely miss, a marginal negative read-across for the construction complex. No analyst target revisions or fresh catalysts are in front of us. Net: a moderate story doing moderate work against a moderately unfavorable rates backdrop, with no acute pressure in either direction.
Verify before trusting this (4)
- Whether AMRZ issues its own guidance or pre-announcement that either validates or cracks the consolidation-accretion story
- Peer prints (ROAD, building products names) to gauge cycle direction
- Any sell-side initiations or target revisions - a fresh spin typically sees coverage ramp and tone shifts matter
- 10y yield direction - a break above 4.8% or back below 4.4% would materially change pressure on the cyclical bid
This lens hasn't been run for this ticker yet.